ADAPT (Achieving Durable Remission via Adaptive Pro-Survival Targeting in Acute Myeloid Leukaemia)

TP53 status and impact on AML prognosis within the ELN 2022 risk classification

S Fleming, XCH Tsai, R Morris, HA Hou, AH Wei

2023-12-07

This study reports the following: (1) frequency of TP53 comutation within each component of the European LeukemiaNet 2022 acute my..